UY39762A - Terapias combinadas - Google Patents
Terapias combinadasInfo
- Publication number
- UY39762A UY39762A UY0001039762A UY39762A UY39762A UY 39762 A UY39762 A UY 39762A UY 0001039762 A UY0001039762 A UY 0001039762A UY 39762 A UY39762 A UY 39762A UY 39762 A UY39762 A UY 39762A
- Authority
- UY
- Uruguay
- Prior art keywords
- inhibitor
- agent
- combinations
- effective amount
- disclosed
- Prior art date
Links
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 239000003112 inhibitor Substances 0.000 abstract 2
- SRQYLNYQAPCPIR-UHFFFAOYSA-N 4-[4-(5,5-dimethyl-4H-thiazol-2-yl)-1-piperazinyl]-6-propylthieno[2,3-d]pyrimidine Chemical compound N1=CN=C2SC(CCC)=CC2=C1N(CC1)CCN1C1=NCC(C)(C)S1 SRQYLNYQAPCPIR-UHFFFAOYSA-N 0.000 abstract 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 abstract 1
- 229940123974 Cytidine deaminase inhibitor Drugs 0.000 abstract 1
- 229940083266 Dihydroorotate dehydrogenase inhibitor Drugs 0.000 abstract 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 abstract 1
- 102100039905 Isocitrate dehydrogenase [NADP] cytoplasmic Human genes 0.000 abstract 1
- 229940119544 Menin-MLL inhibitor Drugs 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940075628 hypomethylating agent Drugs 0.000 abstract 1
- 230000002519 immonomodulatory effect Effects 0.000 abstract 1
- 239000000138 intercalating agent Substances 0.000 abstract 1
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
- 125000000561 purinyl group Chemical class N1=C(N=C2N=CNC2=C1)* 0.000 abstract 1
- 150000003230 pyrimidines Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
<p>Se divulgan combinaciones que comprenden una cantidad terapéuticamente eficaz de un inhibidor de menina-MLL de Fórmula (I), o una sal farmacéuticamente aceptable o un solvato de este, y una cantidad terapéuticamente eficaz de al menos un agente terapéutico diferente que es un agente hipometilante, un inhibidor de citidina·desaminasa, un agente intercalante de ADN, un análogo de pirimidina, un análogo de purina, un inhibidor de cinasas, un inhibidor de CD20, un inhibidor de IDH, un agente inmunomodulador o un inhibidor de DHODH. También se divulgan métodos para tratar a un sujeto diagnosticado con cáncer utilizando tales combinaciones.</p>
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2021093036 | 2021-05-11 | ||
CN2021100523 | 2021-06-17 | ||
CN2021100522 | 2021-06-17 | ||
CN2022086004 | 2022-04-11 | ||
CN2022086003 | 2022-04-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY39762A true UY39762A (es) | 2022-11-30 |
Family
ID=81753153
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001039762A UY39762A (es) | 2021-05-11 | 2022-05-11 | Terapias combinadas |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP4337215A1 (es) |
JP (1) | JP2024519322A (es) |
KR (1) | KR20240006638A (es) |
CN (1) | CN117337180A (es) |
AU (1) | AU2022271993A1 (es) |
CA (1) | CA3214861A1 (es) |
CO (1) | CO2023014325A2 (es) |
DO (1) | DOP2023000239A (es) |
IL (1) | IL308333A (es) |
MX (1) | MX2023013436A (es) |
PE (1) | PE20240588A1 (es) |
TW (1) | TW202308642A (es) |
UY (1) | UY39762A (es) |
WO (1) | WO2022237719A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024114666A1 (en) * | 2022-11-30 | 2024-06-06 | Janssen Pharmaceutica Nv | Combinations comprising a menin-mll inhibitor and a bcl-2 inhibitor |
WO2024114664A1 (en) * | 2022-11-30 | 2024-06-06 | Janssen Pharmaceutica Nv | Combinations comprising a menin-mll inhibitor and at least one other therapeutic agent |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102037502B1 (ko) | 2014-12-18 | 2019-10-28 | 다케다 야쿠힌 고교 가부시키가이샤 | 고체 상태 형태의 융합된 헤테로아로마틱 피롤리디논 |
KR102436430B1 (ko) * | 2016-06-10 | 2022-08-24 | 비타이 파마슈티컬즈, 엘엘씨 | 메닌-mll 상호 작용의 억제제 |
CN110691779B (zh) * | 2017-03-24 | 2023-10-10 | 库拉肿瘤学公司 | 治疗血液系统恶性肿瘤和尤因肉瘤的方法 |
WO2020069027A1 (en) * | 2018-09-26 | 2020-04-02 | Kura Oncology, Inc. | Treatment of hematological malignancies with inhibitors of menin |
TW202104207A (zh) | 2019-04-17 | 2021-02-01 | 美商健生生物科技公司 | 二氫乳清酸脫氫酶抑制劑 |
CN118255774A (zh) | 2019-12-19 | 2024-06-28 | 詹森药业有限公司 | 取代的直链螺环衍生物 |
-
2022
- 2022-05-09 KR KR1020237042472A patent/KR20240006638A/ko unknown
- 2022-05-09 MX MX2023013436A patent/MX2023013436A/es unknown
- 2022-05-09 PE PE2023002970A patent/PE20240588A1/es unknown
- 2022-05-09 CN CN202280034524.5A patent/CN117337180A/zh active Pending
- 2022-05-09 EP EP22725157.6A patent/EP4337215A1/en active Pending
- 2022-05-09 CA CA3214861A patent/CA3214861A1/en active Pending
- 2022-05-09 WO PCT/CN2022/091678 patent/WO2022237719A1/en active Application Filing
- 2022-05-09 IL IL308333A patent/IL308333A/en unknown
- 2022-05-09 AU AU2022271993A patent/AU2022271993A1/en active Pending
- 2022-05-09 JP JP2023568688A patent/JP2024519322A/ja active Pending
- 2022-05-10 TW TW111117440A patent/TW202308642A/zh unknown
- 2022-05-11 UY UY0001039762A patent/UY39762A/es unknown
-
2023
- 2023-10-25 CO CONC2023/0014325A patent/CO2023014325A2/es unknown
- 2023-10-27 DO DO2023000239A patent/DOP2023000239A/es unknown
Also Published As
Publication number | Publication date |
---|---|
TW202308642A (zh) | 2023-03-01 |
PE20240588A1 (es) | 2024-03-21 |
WO2022237719A1 (en) | 2022-11-17 |
DOP2023000239A (es) | 2024-04-30 |
CA3214861A1 (en) | 2022-11-17 |
KR20240006638A (ko) | 2024-01-15 |
EP4337215A1 (en) | 2024-03-20 |
IL308333A (en) | 2024-01-01 |
CN117337180A (zh) | 2024-01-02 |
CO2023014325A2 (es) | 2023-10-30 |
MX2023013436A (es) | 2023-12-12 |
AU2022271993A1 (en) | 2024-01-04 |
JP2024519322A (ja) | 2024-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY39762A (es) | Terapias combinadas | |
Elder et al. | HCMV latency: what regulates the regulators? | |
Messaoudi et al. | Toward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide | |
Kanai et al. | Oncolytic herpes simplex virus vectors and chemotherapy: are combinatorial strategies more effective for cancer? | |
PE20221259A1 (es) | Uso del inhibidor de fak en la preparacion de un farmaco para el tratamiento contra tumores con mutacion nras | |
Smith et al. | Oncolytic viral therapy: targeting cancer stem cells | |
Zaoui et al. | Chemovirotherapy for head and neck squamous cell carcinoma with EGFR-targeted and CD/UPRT-armed oncolytic measles virus | |
WO2006133099A3 (en) | Sirna microbicides for preventing and treating viral diseases | |
MX2021005651A (es) | Combinacion farmaceutica para el tratamiento contra el cancer. | |
Holzmüller et al. | YB‐1 dependent virotherapy in combination with temozolomide as a multimodal therapy approach to eradicate malignant glioma | |
Deng et al. | Oncolytic and immunologic cancer therapy with GM-CSF-armed vaccinia virus of Tian Tan strain Guang9 | |
CL2021002533A1 (es) | Composiciones y métodos para el tratamiento de enfermedades o trastornos asociados con kras | |
JP2017533222A5 (es) | ||
Dai et al. | Cancer therapy with a CRISPR-assisted telomerase-activating gene expression system | |
Kochneva et al. | Oncolytic poxviruses | |
MX2021001056A (es) | Composiciones de agente de acido ribonucleico bicatenario (arnbc) de virus de la hepatitis b (vhb) y metodos de uso de las mismas. | |
Boulware et al. | Triplex‐forming oligonucleotides targeting c‐Myc potentiate the anti‐tumor activity of gemcitabine in a mouse model of human cancer | |
Shen et al. | Oncolytic adenovirus mediated Survivin knockdown by RNA interference suppresses human colorectal carcinoma growth in vitro and in vivo | |
UY39761A (es) | Terapias combinadas | |
CN110520526B (zh) | 基因改造柯萨奇病毒和药物组合物 | |
JP2017515847A5 (es) | ||
MX2018011283A (es) | Compuestos de cinnolin-4-amina y su uso en el tratamiento del cancer. | |
CN103667347A (zh) | 一种高效表达抗癌基因的受特定miRNA调控的在胶质瘤细胞中特异增殖的腺病毒及其用途 | |
BR112022003220A2 (pt) | Uma composição farmacêutica para tratar câncer usada para um paciente tendo marcador genético específico | |
Allan et al. | High-throughput screening to enhance oncolytic virus immunotherapy |